With the anticipated pricing reforms poised to become reality, it is time to assess what impact they will have on new product launches and pricing. Elevate your understanding of how to position your product under the new guidelines. Gain insight to help you:
Successfully manage the impact of pricing reform on your company’s bottom line
Due to be launched by 2023, the new national drug agency recently announced by the federal government will totally transform the pharmaceutical market in Canada. Gain insight into what this will mean for your organization. Advance your preparedness strategy by learning:
Advance your understanding of the potential impact the new national drug agency could have on your organization.
The move toward the establishment of a national drug agency will cause some disruption to the normal approval process while its final structure takes shape. Get the insight you need to understand what changes may be on the horizon for new drug submissions. Walk away with knowledge that will help you:
Be on top of new developments for PLA submissions
Having the clearest picture possible regarding how a broad cross-section of patients will react to new drugs is critical for government payers and patient groups. Explore current innovation and the progress of Health Canada’s RWE project launched in 2018 to improve the value, efficacy and impact of medicines. Take away strategies to help you:
Work with stakeholders to prove and improve the efficacy of your medicines.
Senior Representative, IQVIA
New technology has enabled the development of drug/device and biologic combination products that target specific areas of the body and some which are genetically based. While these innovative therapies are more effective, determining the applicable regulation and path to market can be challenging. Gain insights to:
Anticipate and adapt to changes underway in the approval of combination products.
There are many possible approaches that could be taken to establishing a national pharmacare program. Understanding what direction is emerging from discussions among stakeholders as the most likely to taken once plans are actually underway, will be critical for your pricing and market access strategy. Gain insights for your organization through discussion about:
Hear the latest discussions and prepare your organization for the new era in pharmacare.
Along with the public sector, private payers have also increased their scrutiny of the effectiveness and value for money represented by the drugs they approve for their formularies. Should a national pharmacare program be established, the use of pharmacoeconomics as an evaluative tool seems likely to increase, and provide greater harmonization between the standards of public and private payers for evaluating new drug submissions. Gain insight that will help you craft your market access strategy by learning:
Understand how private payer market access is changing and how you can adapt.
In the face of constantly rising drug costs, employers are having to implement strategies to ensure their plans are sustainable. Learn what measures they are adopting to address skyrocketing drug prices. Walk away with actionable insights to inform your forward strategy by:
Ensure your market access plan has the best shot at success by understanding what employers need.
The Report of the Standing Committee on Health titled “Towards Open Science: Promoting Innovation in Pharmaceutical Research and Development and Access to Affordable Medications both in Canada and Abroad” included nine recommendations which, if adopted, would significantly alter drug development pricing and market access in Canada. Inform your market access strategy with greater insight into changing industry dynamics. Walk away with a roadmap to:
Anticipate change to industry dynamics that could significantly impact your market access and pricing strategies
Canada’s relatively small market has been viewed as an obstacle to attracting drug R&D. That could change if a new approach were adopted that included incentives to conduct R&D in Canada. Take back to your team insights to:
Analyze what benefits could be gained by offering incentives to attract R&D to Canada.
While other countries have adopted measures to reign in the skyrocketing prices of new therapies, the U.S. has resisted adopting this approach – until now. The Trump administration has set lowering drug prices as a key goal and has put forward proposals to achieve this, which if successful, could have a significant impact both within and beyond the U.S. Gain key insights into:
Ensure your company is on top of emerging price developments in the U.S
The new North American trade agreement extends data protection for biologics from 8 to 10 years. While this provides greater opportunities for Brand manufacturers, it may create greater push-back from payers trying to keep their costs at sustainable levels. Discover the probable outcome of this extended protection and fine-tune your strategy by learning:
Prepare your company for additional data protection for biologics under USMCA.
Individualized medicine is proving to be an exciting emerging area that is already having a tremendously positive impact for patient diagnostics and treatment. The Centre for Genetic Medicine at Sickkids is on the forefront of this radical shift in how we think about treating patients. Gain valuable insight into:
Prepare your organization for the transformation precision medicine will bring.
Developing, delivering and funding treatment for patients with rare diseases has become the single biggest challenge for payers, patients and manufacturers. With a growing consensus that a new drug development model is needed, the question becomes what form should it take? Get the latest on how this question may be resolved. Shape your strategy by hearing the latest views on:
Understand how the drug development model could fundamentally change for rare diseases.
The extremely high cost of some new medicines has been garnering a lot of attention lately. However, there are economic benefits of these therapies reduce patient treatments. Gain greater understanding of the ROI new medicines represent to incorporate into your analysis and decision-making. Walk away with insight to:
Get the bigger picture of the return on investment of innovative medicines.
The growth of the biosimilar market has been sluggish due to a number of reasons that include regulatory requirements, production costs, patient preferences and a reluctance on the part of some physicians to prescribe them. Yet as they represent significant cost savings, their adoption will only increase. Heighten your awareness of the increased market impact and future direction for biosimilars. Obtain useful insights to help you:
Improve the path to market for biosimilars and achieve lower treatment costs.
A key feature of new life-saving biologic medicines is the patient support programs offered by Brands that patients rely on to ensure their treatment stays on track. Offering similar patient support has represented a huge challenge for biosimilars that may now be overcome, finally enabling them to be adopted at a far higher rate. Revise your biosimilar listing strategy with the latest news on this ground-breaking development by learning:
Be on top of this game-changing development for biosimilars, patients and payers.
When applied to clinical trials, blockchain technology has the potential to streamline their complexity and offer huge improvements to efficiency, data integrity, and transparency. Gain insight into how blockchain could improve your market access process through higher quality clinical trials and documentation. Advance your market access strategy by learning:
Transform your market access strategy by incorporating blockchain technology into your clinical trials
The recent surge of serious interest in cannabis as an effective treatment for a variety of conditions including PTSD, has exposed some gaps in our current market access system. However, as greater amounts of data and evidence are being gathered about its therapeutic value, greater interest and acceptance is being generated among payers. Hone your medicinal cannabis strategy by:
Discover market access strategies for cannabis products in an evolving market.
The pan-Canadian Pharmaceutical Alliance (pCPA) administers the formal process for getting new drugs to the marketplace. Source insights to manage and optimize your submission. Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:
Develop your successful pCPA strategy through this hands-on interactive workshop.